A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

The randomised trial saw over half of patients dosed with Sunosi were able to achieve clinical response to the therapy ...

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.

Axsome Therapeutics’ Phase III Focus trial investigating its attention-deficit hyperactivity disorder (ADHD) therapy, Sunosi (solriamfetol), has met its primary endpoint and provided a ...

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

Sunosi is a prescription drug that’s prescribed for excessive daytime sleepiness (EDS) in certain adults. It is a controlled substance. Sunosi is a part of the class of drugs called dopamine ...

Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...

Centessa Pharmaceuticals plc shifts focus to ORX750 for sleep disorders after discontinuing SerpinPC. Click here to find out ...

Axsome Therapeutics said it's dopamine and norepinephrine reuptake inhibitor solriamfetol (Sunosi), approved for excessive daytime sleepiness, failed to reduce symptoms of major depressive disorder in ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

Axsome Therapeutics AXSM announced that the phase III FOCUS study, which evaluated solriamfetol for the treatment of ...